rs774508076
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 16P and 4B. PVS1PP5_Very_StrongBS2
The NM_017841.4(SDHAF2):c.165G>A(p.Trp55*) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000479 in 1,461,842 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_017841.4 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251250Hom.: 0 AF XY: 0.0000295 AC XY: 4AN XY: 135784
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461842Hom.: 0 Cov.: 32 AF XY: 0.00000688 AC XY: 5AN XY: 727230
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary pheochromocytoma-paraganglioma Pathogenic:2
This sequence change creates a premature translational stop signal (p.Trp55*) in the SDHAF2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SDHAF2 are known to be pathogenic (PMID: 22241717, 26096992). This variant is present in population databases (rs774508076, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with SDHAF2-related conditions. ClinVar contains an entry for this variant (Variation ID: 384524). For these reasons, this variant has been classified as Pathogenic. -
This variant changes 1 nucleotide in exon 2 of the SDHAF2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has not been reported in individuals affected with SDHAF2-like disorders, but a different variant with the same protein consequence (c.164G>A, p.Trp55*) has been observed in an individual with a bilateral carotid body tumor (PMID: 36597280). This variant has been identified in 5/251250 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss-of-function variants in SDHAF2 are an expected mechanism of disease (PMID: 22241717, 26096992). Based on the available evidence, this variant is classified as Pathogenic. -
Paragangliomas 2 Pathogenic:1
This variant changes 1 nucleotide in exon 2 of the SDHAF2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has not been reported in individuals affected with SDHAF2-like disorders, but a different variant with the same protein consequence (c.164G>A, p.Trp55*) has been observed in an individual with a bilateral carotid body tumor (PMID: 36597280). This variant has been identified in 5/251250 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss-of-function variants in SDHAF2 are an expected mechanism of disease (PMID: 22241717, 26096992). Based on the available evidence, this variant is classified as Pathogenic. -
not provided Pathogenic:1
Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 36597280, 31687641) -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.W55* pathogenic mutation (also known as c.165G>A), located in coding exon 2 of the SDHAF2 gene, results from a G to A substitution at nucleotide position 165. This changes the amino acid from a tryptophan to a stop codon within coding exon 2. A similar variant resulting in the same protein truncation (c.164G>A, p.W55*) has been reported in a Japanese patient who was diagnosed with bilateral paragangliomas at age 73 (Yoshihama K et al. Clin Genet, 2023 Jan;:). This c.165G>A variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
not specified Uncertain:1
The p.Trp55X variant in SDHAF2 has not been previously reported in individuals w ith SDHAF2-associated hereditary paraganglioma-pheochromocytoma syndromes but ha s been identified in 3/66432 European chromosomes by the Exome Aggregation Conso rtium (ExAC, http://exac.broadinstitute.org; dbSNP rs774508076). This nonsense v ariant leads to a premature termination codon at position 55, which is predicted to lead to a truncated or absent protein. Although this variant is expected to severely impact the protein, the spectrum of disease-causing variants is not we ll defined for SDHAF2. In summary, the clinical significance of the p.Trp55X var iant is uncertain. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at